Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Kallesh Danappa Jayappa"'
Publikováno v:
Virology Journal, Vol 16, Iss 1, Pp 1-14 (2019)
Abstract Background HIV integrase (IN) and its cellular cofactors, including lens-epithelium-derived growth factor (LEDGF/p75), Ku70, p300, and Rad52, are subject to small ubiquitin-like modifier (SUMO) modification. In addition to covalent SUMOylati
Externí odkaz:
https://doaj.org/article/abe7d5312ff6450985fbffd68e5fb725
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 3, Iss C (2014)
Human immunodeficiency virus type 1 (HIV-1) drug resistance and the latent reservoir are the two major obstacles to effectively controlling and curing HIV-1 infection. Therefore, it is critical to develop therapeutic strategies specifically targeting
Externí odkaz:
https://doaj.org/article/c7962b05802543778546a43e62afaca6
Autor:
B. Dharmaveer Shetty, Konrad J. Cios, Kallesh Danappa Jayappa, Vicki L. Gordon, Craig A. Portell, Michael J. Weber, Briana Wilson, Krista Isaac, Michael E. Williams, Puja C. Arora, Timothy P. Bender, Christopher Morris, Shekhar Saha
Publikováno v:
Blood Adv
The Bcl-2 inhibitor venetoclax has yielded exceptional clinical responses in chronic lymphocytic leukemia (CLL). However, de novo resistance can result in failure to achieve negative minimal residual disease and predicts poor treatment outcomes. Cons
Autor:
Goutham Narla, Shekhar Saha, Timothy P. Bender, Christopher Morris, Krista Isaac, Caroline Farrington, Kallesh Danappa Jayappa, Michael J. Weber, Vicki L. Gordon, Craig A. Portell, Michael E. Williams
Publikováno v:
Blood. 136:15-17
The advent of molecularly targeted therapies has revolutionized the treatment of Non-Hodgkin's Lymphoma (NHL), including Chronic Lymphocytic Leukemia (CLL). Venetoclax (VEN, an inhibitor of Bcl-2) and ibrutinib (IBR, an inhibitor of BTK) generated ex
Autor:
Shekhar Saha, Michael E. Williams, Michael J. Weber, Craig A. Portell, Goutham Narla, Krista Isaac, Caroline Farrington, Christopher Morris, Timothy P. Bender, Vicki L. Gordon, Kallesh Danappa Jayappa
Publikováno v:
Cancer Research. 81:937-937
The Bcl-2 inhibitor venetoclax (VEN) shows clinical activity in Chronic Lymphocytic Leukemia (CLL), and the response is potentiated when combined with the BTK inhibitor ibrutinib (IBR) (Portell et al. 2019; Tam et al. 2018). However, many VEN or VEN+
Autor:
Stefan Bekiranov, Timothy P. Bender, Julia Wulfkuhle, Emanuel F. Petricoin, Michael J. Weber, Mark J. Axelrod, Vicki L. Gordon, Kallesh Danappa Jayappa, Michael E. Williams, Rosa I. Gallagher, Brian J. Capaldo, L. Kyle Brett, Craig A. Portell
Publikováno v:
Blood Advances. 1:933-946
De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To iden
Publikováno v:
Virology Journal
Virology Journal, Vol 16, Iss 1, Pp 1-14 (2019)
Virology Journal, Vol 16, Iss 1, Pp 1-14 (2019)
Background HIV integrase (IN) and its cellular cofactors, including lens-epithelium-derived growth factor (LEDGF/p75), Ku70, p300, and Rad52, are subject to small ubiquitin-like modifier (SUMO) modification. In addition to covalent SUMOylation, SUMO
Autor:
Michael E. Williams, Michael J. Weber, Vicki L. Gordon, Timothy P. Bender, Kallesh Danappa Jayappa, Craig A. Portell, Goutham Narla
Publikováno v:
Blood. 132:2649-2649
Ibrutinib (IBR), an inhibitor of Bruton's Tyrosine Kinase (Btk) and venetoclax (VEN), an inhibitor of Bcl-2 have been used in Chronic Lymphocytic Leukemia (CLL), but single agent responses to these drugs are often incomplete and not durable. We previ
Autor:
Konrad J. Cios, Michael J. Weber, Vicki L. Gordon, Puja C. Arora, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Kallesh Danappa Jayappa
Publikováno v:
Blood. 132:4120-4120
Responses to single-agent ibrutinib (IBR) or venetoclax (VEN) in Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) are often incomplete suggesting drug combinations are needed to overcome de novo and acquired resistance. We previously
Autor:
Guojun Wu, Xiaojian Yao, Shuiping Liu, Liyu Chen, Gary P. Kobinger, Mark A. Wainberg, Zhujun Ao, Kallesh Danappa Jayappa
Publikováno v:
Antimicrobial Agents and Chemotherapy. 57:3547-3554
In the absence of an effective vaccine against HIV-1 infection, anti-HIV-1 strategies play a major role in disease control. However, the rapid emergence of drug resistance against all currently used anti-HIV-1 molecules necessitates the development o